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ttp://dx.doi.org/10.1016/j.jmoldx.2013.01.001Patients with cystic ﬁbrosis (CF) manifest a multisystemic disease due to mutations in the gene
encoding the cystic ﬁbrosis transmembrane conductance regulator (CFTR); despite extensive testing of
coding regions, a proportion of CF alleles remains unidentiﬁed. We studied 118 patients with CF and
CFTR-related disorders, most with one or both unknown mutations after the scanning of CFTR coding
regions, and a non-CF control group (nZ 75) by sequencing the 6000-bp region at the 50 of the CFTR
gene. We identiﬁed 23 mutations, of which 9 were novel. We expressed such mutations in vitro using
four cell systems to explore their functional effect, relating the data to the clinical expression of each
patient. Some mutations reduced expression of the gene reporter ﬁreﬂy luciferase in various cell lines
and may act as disease-causing mutations. Other mutations caused an increase in luciferase expression
in some cell lines. One mutation had a different effect in different cells. For other mutations, the
expression assay excluded a functional role. Gene variants in the large 50 region may cause altered
regulation of CFTR gene expression, acting as disease-causing mutations or modiﬁers of its clinical
phenotype. Studies of in vitro expression in different cell systems may help reveal the effect of such
mutations. (J Mol Diagn 2013, 15: 331e340; http://dx.doi.org/10.1016/j.jmoldx.2013.01.001)Supported by grants from Fondazione per la ricerca sulla Fibrosi Cistica
(Verona, Italy, Delegazione Basilicata), Regione Campania (DGRC 1901/
09), and Ministero della Salute (L.502/92, annualità 2008).Cystic ﬁbrosis (CF) is the most frequent lethal inherited
disorder among white people, with an incidence of 1:2500
newborns. It depends on alterations of the chloride channel
expressed by most epithelial cells and encoded by the cystic
ﬁbrosis transmembrane regulator gene (CFTR).1 The diag-
nosis of CF is based on symptoms, sweat chloride levels, and
molecular analysisﬁndings.However, causativemutations are
identiﬁed in 90% to 95% of CF chromosomes using scanning
procedures to analyze whole coding regions of CFTR2 and
large gene rearrangements,3 and this percentage is lower instigative Pathology
.CFTR-related disorders (CFTR-RDs).4 It is conceivable that
some disease-causingmutations lie in gene regulatory regions.
Furthermore, a known feature of CF is the scarce
genotype-phenotype correlation and the different expression
of the disease in patients with CF bearing the same geno-
type5 and in sib-pairs with CF.6 A variety of modiﬁer genes
Giordano et alof the CF phenotype7 can explain the phenotypic hetero-
geneity, but each acts in a small percentage of patients with
CF.8,9 These results prompted studies of noncoding regions
of CFTR, including intronic10 and ﬂanking regions, poten-
tially involved in the regulation of gene expression.11
The CFTR gene shows clear temporal and developmental
regulation of its expression, but the molecular mechanisms
underlying the transcriptional control in different tissues and
organs are still poorly understood.11 In fact, few regulatory
elements have been detected so far. Analysis of 3.8 kb of
genomic sequence upstream of exon 1 of the CFTR gene
revealed high GC content (65%), no TATA box, multiple
transcriptional start sites, and several potential Sp1 and AP-1
protein binding sites.11 Moreover, the presence of conserved
sequence tags12 conﬁrms that the region at the 50 of CFTRmay
have a relevant role in the regulation of CFTR expression.
Mutations in this region may impair the interaction between the
gene and regulatory factors and act as disease-causing muta-
tions; moreover, theymaymodulate expression of the gene (and
thus of the disease) at different organs and tissue levels. Some
examples of mutations that interfere with CFTR transcriptional
activity13 have been described in the more proximal 50 region of
CFTR in patients with CF14 and CFTR-RDs,15 but for other
mutations identiﬁed in single patients (such as those reported in
the Cystic Fibrosis Mutation Database, http://www.genet.
sickkids.on.ca/Home.html, last accessed March 13, 2013.), the
lack of expression studies did not permit deﬁnition of the
functional role.We studied the 6000-bp region at the 50 ofCFTR
in a large group of patients with CF and CFTR-RDs, most with
one or both unknown mutations after scanning of the CFTR
coding region, and in non-CF controls. We expressed some
mutations in four cell systems to deﬁne their effect.Materials and Methods
Participants
This study was performed on 118 unrelated Italian patients
(Table 1) affected by CF (58 cases) orCFTR-RDs (60 cases). In
detail, we studied i) 20 patients with CF homozygous for the
F508del mutation, aged >18 years, and classiﬁed as havingTable 1 Main Features of the 118 Study Patients
Diagnosis CFTR genotype Swe
CF F508del/F508del Posi
CF F508del/F508del Posi
CF Mutation/U Posi
CF Mutation/mutation* Posi
CF Mutation/TG12-T5-470V Bord
CF U/U Posi
CBAVD Mutation/U Neg
CBAVD U/U Neg
Recurrent pancreatitis Mutation/U Neg
Disseminated bronchiectasis Mutation/U Neg
*The patient originally had the genotype 2789 þ 5G>A/unknown; during the
CF, cystic ﬁbrosis; CBAVD, congenital bilateral absence of vasa deferents; L, li
332severe pulmonary and liver expression (n Z 10) or mild
pulmonary and no liver expression (n Z 10) as previously
described7,8; ii) 38 patientswithCFwith one (nZ32)or both (n
Z 6) undetected mutations after analysis of the most frequent
CFTR mutations in this population,16 CFTR gene scanning,2
and the search for large gene rearrangements3; and iii) 60
patientswithCFTR-RDs4whohadnormal sweat chloride levels
(ie, chloride<60 mEq/L) on two test occasions, no familiarity
for CF, and the absence of colonization by Pseudomonas aer-
uginosa and other pathogens typically identiﬁed in sputum from
patients with CF. None of these patients met the criteria for CF
diagnosis.17 Of these 60 patients with CFTR-RDs, 11 had
recurrent pancreatitis, 11 had disseminated bronchiectasis, and
38hadcongenital bilateral absenceof vasadeferentia (CBAVD)
characterized by azoospermia with a low semen plasma volume
(<1.5 mL) and low pH (<7.5), bilateral nonpalpable vasa
deferentia, absence of the distal part of the epididymis, and
hypoplasia of the seminal vesicles conﬁrmed by ultrasound.
Finally, we studied 75 unrelated non-CF controls from the same
geographic area. All the participants (guardians in the case of
minors) providedwritten informed consent to anonymously use
a DNA sample and clinical data for research purposes.
Molecular Analysis of CFTR Coding Regions
Genomic DNA was extracted from whole blood samples
collected on EDTA (Nucleon BACC3; Amersham Biosci-
ences, Little Chalfont, UK). To detect CFTR gene mutations,
we analyzed a panel of the most frequent mutations in Italy
and then scanned all 27 exons and the intronic boundaries by
denaturing gradient gel electrophoresis and gene sequencing.2
Large CFTR rearrangements were tested by scanning all the
CFTR exons using a commercial kit based on quantitative
PCR followed by capillary electrophoresis (MLPA SALSA
kit; MRC-Holland, Amsterdam, The Netherlands).
Molecular Analysis of the 50 CFTR Region
Molecular analysis of the 6000-bp region at the 50 of the gene
was performed by direct sequencing. DNA was ampliﬁed as
seven fragments of various lengths (400 to 900 bp) by PCRat test results Clinical expression No. of cases
tive PI, severe L, severe P 10
tive PI, no L, mild P 10
tive Variable 30
tive Severe 1
erline Mild 1
tive Variable 6
ative CBAVD alone 32
ative CBAVD alone 6
ative PS, no L, no (or mild) P 11
ative PS, no L, no (or mild) P 11
present study, we revealed the second mutation (ie, Y849X).
ver expression; P, pulmonary expression.
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Table 2 Sequences of Oligonucleotides
Primer name Primer sequence
CFTR promoter sequencing primers
Fragment from 263 to þ97 forward 50-CCGGTAATTACGCAAAGCAT-30
Fragment from 263 to þ97 reverse 50-CTGGGCTCAAGCTCCTAATG-30
Fragment from 1276 to 333 forward 50-TTTGGGTGACCACAAGTCAA-30
Fragment from 1276 to 333 reverse 50-AACGCTGGAGGACAGAAGAA-30
Fragment from 2219 to 1256 forward 50-TTTCTGCTTTCCTGTTTCATTG-30
Fragment from 2219 to 1256 reverse 50-TTGACTTGTGGTCACCCAAA-30
Fragment from 3138 to 2197 forward 50-TGTAAGAAGCACCCAGCACA-30
Fragment from 3138 to 2197 reverse 50-CAATGAAACAGGAAAGCAGAAA-30
Fragment from 4078 to 3118 forward 50-GCTAAGTGTGGTGCCAGGAT-30
Fragment from 4078 to 3118 reverse 50-TGTCTGGGTCTTCTTACA-30
Fragment from 5049 to 4058 forward 50-GCAAAGGGACATTTTCACCA-30
Fragment from 5049 to 4058 reverse 50-ATCCTGGCACCACACTTAGC-30
Fragment from 6000 to 5029 forward 50-GTGACTTCATGTCCCGTCCT-30
Fragment from 6000 to 5029 reverse 50-TGGTGAAAATGTCCCTTTGC-30
Expression vector construct primers
Construct 1 forward 50-TTTCTGCTTTCCTGTTTCATTG-30
Construct 1 reverse 50-GACCCGAGTTCGAGGATTAC-30
Construct 2 forward 50-GTGACTTCATGTCCCGTCCT-30
Construct 2 reverse 50-ACCACTTTTACAGGGAAACG-30
Construct 3 forward 50-TGTTAGTGCCCATGTGCAAT-30
Construct 3 reverse 50-AACTGAACACCAGTGGGTTT-30
Site-directed mutagenesis primers
542pGL3B forward 50-ATACGAAAGGCACACTTTCCTTCCCTTTTC-30
542pGL3B reverse 50-GGGAAGGAAAGTGTGCCTTTCGTATATCAA-30
680pGL3B forward 50-TTGGAGTTCACGCACCTAAACCTGAAACTA-30
680pGL3B reverse 50-TCAGGTTTAGGTGCGTGAACTCCAAGGGTG-30
1176pGL3B forward 50-TACTTTCCTTTGAGTTTTTCAATTCAAACACAATGTATGCTTGC-30
1176pGL3B reverse 50-CATACATTGTGTTTGAATTGAAAAACTCAAAGGAAAGTAAAAAT-30
c.-1773_-1772delATpGL3B forward 50-GAGTTCAATCACGTCTGGGAAAAGTCAATAG-30
c.-1773_-1772delATpGL3B reverse 50-CTTTTCCCAGACGTGATTGAACTCACCACAT-30
2068pGL3B forward 50-ACACAGTGATAGGAATAATGGTTTAGAACT-30
2068pGL3B reverse 50-TAAACCATTATTCCTATCACTGTGTAATAC-30
3500pGL3B forward 50-CACTGTTGAATAGCTGTGGCTGTTCTTACC-30
3500pGL3B reverse 50-AACAGCCACAGCTATTCAACAGTGGGCCAC-30
5183pGL3B forward 50-TAAGACTTCCTTAATAAGAAACTACCTTTA-30
5183pGL3B reverse 50-GGTAGTTTCTTATTAAGGAAGTCTTAAAGA-30
5782pGL3B forward 50-TATTGCCTTTTCTCAGATATCAGGTTATGAGAATAATA-30
5782pGL3B reverse 50-ATTCTCATAACCTGATATCTGAGAAAAGGCAATATGTA-30
Analysis of CFTR 50 Region Mutationsusing the Veriti thermal cycler (Applied Biosystems, Foster
City, CA) and the HotStarTaq DNA polymerase kit (Qiagen
Inc., Valencia, CA); the sequences of the PCR primers are
listed in Table 2. The PCR was standardized according to the
manufacturer’s instructions. The assay was performed in a
30-mL reaction mixture containing 2 mL of genomic DNA
(120 ng), 8 mmol/L of each primer, 3 mL of the 10X buffer,
10 mmol/L dNTPs, HotStarTaq DNA polymerase (0.75 U per
reaction), and autoclaved water. The cycling conditions were
as follows: HotStarTaq DNA polymerase activation at 95C
for 15 minutes, 50 cycles at 94C for 30 seconds, 54 to 58C
for 30 seconds, and 72C for 1 minute, with a ﬁnal extension
at 72C for 10 minutes. All ampliﬁcation products were
checked by electrophoresis in agarose gel (20 g/L) with the
Tris-borate-EDTA buffer and then were sequenced.The Journal of Molecular Diagnostics - jmd.amjpathol.orgNomenclature of Mutations of CFTR
The recommendations of the Human Genome Variation
Society18 were followed in naming the mutations, usingþ 1 as
the A of the initiation ATG codon in the reference sequence
NM_000492.3. Table 3 reports the ofﬁcial nomenclature and
the current legacy name for each mutation.
Real-Time PCR of CFTR Transcripts in Some Cell Lines
Total RNA was isolated from frozen pellets of the HepG2,
HeLa, PanC-1, and A549 cell lines using TRIzol reagent
(Invitrogen, Carlsband, CA) according to the manufacturer’s
protocol. RNA concentration and purity were determined
using a NanoDrop ND-1000 spectrophotometer (NanoDrop,333
Table 3 Gene Variants Identiﬁed in the Region of 6000 bp at the 50 of CFTR
Variant (cDNA name) Variant (legacy name)
No. (%) of alleles
Control subjects
(150 alleles)
Patients with CF
(116 alleles)
Patients with CFTR-RDs
(120 alleles)
c.-274C>A -142C>A 5 (3.3) 0 0
c.-275G>A* -143G>A 2 (1.3) 0 1 (0.8)
c.-461A>G -329A/G 3 (2.0) 0 1 (0.6)
c.-593A>G -461A->G 2 (1.3) 2 (1.7) 2 (1.7)
c.-674T>C* -542T>C 0 0 3 (2.5)
c.-737G>A 5 (3.3) 0 0
c.-751A>G 2 (1.3) 2 (1.7) 2 (1.7)
c.-812T>G -680T>G 2 (1.3) 0 2 (1.7)
c.-869T[8_9] -790T9/8 4 (2.7) 1 (0.9) 0
c.-887C>T -816C->T 4 (2.7) 1 (0.9) 0
c.-966T>G -834T>G 9 (6.0) 2 (1.7) 1 (0.8)
c.-1043dupT -911dupT 6 (4.0) 0 0
c.-1043delT -911delT 1 (0.6) 0 1 (0.8)
c.-1308A>G -1176A>G 0 3 (2.6) 0
c.-1773_-1772delAT* -1641-1640delAT 0 2 (1.7) 0
c.-2200G>A* -2068G>A 2 (1.3) 1 (0.9) 0
c.-3136T>G* -3004T>G 4 (2.7) 0 0
c.-3632G>T* -3500G>T 2 (1.3) 1 (0.9) 0
c.-3966T>C -3834T>C 40 (26.7) 83 (71.6) 24 (20.0)
c.-5315G>A* -5183G>A 1 (0.6) 0 1 (0.8)
c.-5671C>T -5539C>T 41 (27.3) 88 (75.9) 29 (24.2)
c.-5914A>G* -5782A>G 0 0 1 (0.8)
c.-5947T>G* -5815T>G 4 (2.7) 0 0
*Novel variants.
Giordano et alWilmington, DE); reverse transcriptionwas performed on 1mg
of total RNA resuspended in diethyl-pyrocarbonateetreated
Nanopure water using a QuantiTect reverse transcription kit
(Qiagen Inc.) and the protocol supplied by the manufacturer.
To check levels of CFTR transcripts in the HepG2, HeLa,
PanC-1, andA549cell lines, relative quantiﬁcation of real-time
PCR was performed in duplicate using the LightCycler 480
ProbesMaster containingCFTR primers and a TaqManCFTR
probe (CFTR and H. sapiens, ID. Assay 102716; Roche
Diagnostics GmbH,Mannheim, Germany). Ampliﬁcationwas
performed using the LightCycler 480 systems for real-time
PCR (Roche) with a two-step PCR protocol (preincubation
of 10minutes at 95C followed by 45 cycles of ampliﬁcation at
95C for 10 seconds, 60C for 10 seconds, and 72C for 1
second). mRNA quantiﬁcation results were normalized using
the glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
gene (ID. Assay 101128; Roche) as an endogenous control. In
all the studies, each sample was run in triplicate, and the CT
method (DDCT method) was used to examine the relative
quantiﬁcation of the samples. Fold expression changes were
calculated using the following equation: 2  DDCT.
Reporter Gene Construct and Site-Directed
Mutagenesis
To facilitate the promoter cloning, we divided the region of
6000 bp into three fragments that were cloned progressively.
Construct 1 extends from positions 2219 to 97 (referred to334as the major transcription initiation site), construct 2 extends
from nucleotides 6000 to 5030, and construct 3 extends
from nucleotides5727 to1256. Segments were ampliﬁed
using speciﬁc primers (Table 2), and these primers were
ﬂanked at the 50 end by a synthetic restriction enzyme site; the
reaction was performed using a PfuUltra high-ﬁdelity DNA
polymerase (Stratagene, an Agilent Technologies company,
La Jolla, CA). Construct 1 had at the 50 end an XhoI
restriction site and at the 30 end an XbaI restriction site;
construct 2 had at the 50 end a KpnI restriction site and at the
30 end an XbaI restriction site; and the last fragment had at
both ends an XbaI restriction site. The integrity and accuracy
of the wild-type (WT) cloned promoter regions in the
constructs were checked by DNA sequencing. After this step,
they were inserted in sequence in a temporary expression
vector (pGEM-T vector; Promega Corp., Madison,WI) using
the T4 DNA ligase kit (Promega Corp.). Then, the entire WT
6-kb construct was excised from the pGEM-T vector by
a restriction reaction with KpnI and XhoI endonucleases and
then was ligated into a pGL3-Basic vector (Promega Corp.);
this vector contains a modiﬁed ﬁreﬂy luciferase coding
sequence upstream of the SV40 late poly(A) signal and no
eukaryotic promoter or enhancer sequences. Mutagenesis of
the WTepGL3-Basic 6-kb construct was achieved by using
a QuikChange II XL site-directed mutagenesis kit (Stra-
tagene) according to the manufacturer’s instructions; all the
primers used are listed in Table 2. Subsequently, we checked
for each genetic variant by direct sequencing. Plasmids werejmd.amjpathol.org - The Journal of Molecular Diagnostics
Analysis of CFTR 50 Region Mutationssequenced after site-directed mutagenesis to conﬁrm the
changes and to rule out additional nonspeciﬁc changes.
Cell Culture
Cell lines were purchased from ATCC (Manassas, VA).
Human hepatocellular carcinoma cells (HepG2, ATCC
number HB-8065), human cervical carcinoma cells (HeLa,
ATCC number HB-8065), human lung carcinoma cells
(A549, ATCC number CCL-185), and epithelioid carcinoma
pancreatic duct cells (PanC-1, ATCC number CRL-1469)
were maintained in Dulbecco’s modiﬁed Eagle’s medium
(Gibco Invitrogen, Grand Island, NY) with 10% heat-
inactivated fetal bovine serum (HyClone, Logan, UT)
without the addition of antibiotics; cell cultures were main-
tained in a 5% (v/v) CO2ehumidiﬁed atmosphere at 37C.
Transient Transfection and Gene Expression Assays
For HeLa and A549 cells, transient transfection was per-
formed using Attractene reagent (Qiagen Inc.), whereas
PanC-1 and HepG2 cells were transfected using Lip-
ofectamine 2000 CD and Lipofectamine LTX with Plus
reagent (Invitrogen), respectively, according to the manu-
facturer’s speciﬁcations. All the cells were plated in
a 24-well culture dish 24 hours before the experiments.
HeLa cells were seeded at a density of approximately 8 
104 per well; A549 at 5  104 per well; PanC-1 at 2  104
per well; and HepG2 at 1.2  105 per well. When cells
reached an appropriate conﬂuence (approximately 50% to
60% for HepG2 and PanC-1 cells and 70% to 80% for
HeLa and A549 cells), they were cotransfected with 700 ng
per well of plasmid reporter and 50 ng per well of internal
control pRL-CMV containing Renilla luciferase (Promega
Corp.) driven by a cytomegalovirus promoter to normalize
transfection efﬁciency. Because pGL3-Basic vector lacks
any eukaryotic promoter or enhancer sequences, it was
used as a negative control. Cells were grown for anFigure 1 Regulatory variants identiﬁed in CFTR promoter. Diagram of the chro
region with annotation of the 23 mutations identiﬁed in the present study.
The Journal of Molecular Diagnostics - jmd.amjpathol.orgadditional 24 hours, washed in phosphate-buffered saline,
lysed in 100 mL of passive lysis buffer (Promega Corp.),
collected, and centrifuged for 10 minutes at 12,000 rpm to
remove cell debris. Ten microliters of cleared lysate was
assayed sequentially for ﬁreﬂy and Renilla luciferase
activity using the Dual-Luciferase Reporter Assay system
(Promega Corp.) according to the manufacturer’s recom-
mendations. Luminescence measurements were performed
using a VICTOR3-1420 multilabel counter (PerkinElmer,
Waltham, MA) with a 5-second measurement period;
ﬁreﬂy luciferase activity was normalized to Renilla lucif-
erase activity. Experiments were made at least in duplicate,
and each set of transfections was repeated four times for
each cell line with independently puriﬁed plasmid DNA
preparations and reaction mix.
Statistical Analysis
Comparisons of promoter activity between WT and variant
CFTR promoter constructs from luciferase assays were
conducted by using the unpaired t-test; data were considered
statistically signiﬁcant at P < 0.001; data are expressed as
means  SE of four different assays.
Results
Identiﬁcation of CFTR Regulatory Variants
Molecular analysis of the 6000-bp region at the 50 of the
CFTR gene was performed in all patients with CF and
CFTR-RDs and in control subjects. We identiﬁed 23
mutations, 9 of which are novel (Figure 1). A summary of
these gene variants appears in Table 3. Two mutations have
a high frequency: c.-3966T>C, with an allele frequency
ranging from 20.0% in patients with CFTR-RDs to 71.6% in
patients with CF, and c.-5671C>T, with an allele frequency
ranging from 24.2% in patients with CFTR-RDs to 75.9% in
patients with CF. The high frequency of such mutations inmosome 7q31.2 region containing CFTR and magniﬁcation of the sequenced
335
Figure 2 Relative quantiﬁcation of CFTR mRNA expression in the
HepG2, HeLa, PanC-1, and A549 cell lines. The values of CFTR mRNA are
reported as means  SD ratios to GAPDH housekeeping mRNA.
Giordano et alpatients depends on the linkage disequilibrium of both the
mutations with the F508del, which is the most frequent
mutation in this series of patients. c.-274C>A, c.-737G>A,
c.-966T>G, and c.-1043dupT have allelic frequencies of
3.3%, 3.3%, 6.0%, and 4.0%, respectively, in control
subjects. The other 17 mutations have allelic frequencies
<3.0% and were expressed in vitro.In Vitro Expression of Mutations and Their Functional
Effect on Gene Expression
To study the functional effect of CFTR mutations, we used
four cell systems with different baseline levels of CFTR
expression because such cells would produce different
(levels of) CFTR interactors. We tested CFTR expression by
real time-PCR and reported the result as a ratio to GAPDHTable 4 Luciferase Expression (% Compared with the WT) of Mutated
Mutation A549 PanC-
c.-275G>A* 106.9 (18.3) 99.5
c.-461A>G 96.9 (11.1) 97.5
c.-593A>G 98.6 (13.4) 82.6
c.-674T>C* 57.1 (9.4)y 89.4
c.-751A>G 98.5 (7.2) 120.7
c.-812T>G 91.4 (12.6) 83.6
c.-869T[8_9] 54.5 (11.6)y 53.8
c.-887C>T 88.5 (15.0) 112.3
c.-1043delT 106.3 (11.6) 93.6
c.-1308A>G 86.5 (10.6) 33.6
c.-1773_-1772delAT* 97.3 (9.1) 55.9
c.-2200G>A* 112.8 (10.3) 105.8
c.-3136T>G* 97.6 (11.7) 96.3
c.-3632G>T* 97.6 (7.4) 149.7
c.-5315G>A* 102.8 (18.1) 59.7
c.-5914A>G* 118.5 (12.2) 140.8
c.-5947T>G* 102.6 (12.4) 89.4
*Novel variants.
yValues signiﬁcantly different (P < 0.001) compared with those obtained with
NT, not tested.
336mRNA. As shown in Figure 2, no basal CFTR expression
was found in HepG2 cells, HeLa cells expressed low basal
levels of CFTR mRNA, PanC-1 cells expressed an inter-
mediate basal level of CFTR mRNA, and A549 cells
expressed the highest basal levels of CFTR mRNA.
Thus, we expressed the 17 CFTR mutations in the four cell
systems to determine their functional impact in modulating
CFTR promoter activity compared with the WT sequence.
Table 4 shows the results of the mutations expressed in vitro
and tested with Dual-Luciferase Reporter Assay. Most muta-
tions (ie, c.-275G>A, c.-461A>G, c.-593A>G, c.751A>G,
c.-887C>T, c.-1043delT, c.-3136T>G, c.-5315G>A, and
c.-5947T>G) do not inﬂuence expression of the reporter
system in any of the four cell systems. Four mutations
(ie, c.-674T>C, c.869T[8_9], c.-1308A>G, and c.-1773_
-1772delAT) cause a signiﬁcant reduction in reporter gene
expression in one or more cell systems. The c.-812T>G
mutation and the c.-2200G>A and c.-5914A>G mutations
cause a signiﬁcant increase in gene expression in HepG2 and
HeLa cells, respectively. Finally, the c.-3632G>T mutation
causes a signiﬁcant increase in gene expression in PanC-1 cells
and a signiﬁcant reduction in HepG2 cells.Genotype-Phenotype Correlation
Thus, eight mutations signiﬁcantly modiﬁed the levels of
gene expression in some cell lines (Figure 3). We related such
variants to the clinical expression of the patients (Table 5).
The novel c.-674T>C mutation was identiﬁed in three
patients with CBAVD (cases 1 to 3) with normal sweat
chloride levels and no other signs or symptoms of CF. The
mutation was homozygous in case 1, who was also hetero-
zygous for N1303K; however, the two other patients had theCFTR Promoter in Various Cell Types
1 HeLa HepG2
(21.1) 106.1 (19.1) NT
(11.1) NT 103.9 (12.1)
(7.4) NT NT
(14.1) 79.9 (24.7) 33.2 (5.7)y
(12.7) NT 96.2 (7.1)
(13.7) 81.6 (13.1) 145.7 (14.4)y
(10.8)y NT 95.6 (8.9)
(14.6) NT 97.4 (18.3)
(11.0) 92.2 (14.1) 95.9 (14.7)
(11.0)y 106.2 (20.7) 95.4 (24.6)
(4.5)y 135.8 (23.1) 28.9 (4.2)y
(17.7) 328.0 (29.3)y 113.2 (15.5)
(20.1) 116.5 (19.3) 115.0 (21.3)
(10.9)y 124.0 (16.9) 64.1 (14.8)y
(18.0) 100.0 (11.2) 107.1 (18.1)
(15.7) 209.8 (5.7)y 100.1 (21.4)
(11.1) 97.6 (18.9) 98.4 (13.6)
the WT.
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Figure 3 Relative promoter activity of muta-
tions identiﬁed in the study. Plasmid constructs
expressing ﬁreﬂy luciferase under control of WT or
variant CFTR promoters were individually cotrans-
fected with a Renilla luciferase reporter construct
(pRL-CMV) in the HeLa, PanC-1, A549, and HepG2
cell lines. Fireﬂy luciferase expression was
measured and normalized to that of Renilla lucif-
erase; then, Renilla-normalized promoter activities
for mutated constructs were compared with those
of the WT construct (indicated by the dashed
horizontal line) to provide relative CFTR promoter
activity of the variant. The assay was conducted at
least in duplicate, and each set of transfections
was repeated four times with independently puri-
ﬁed plasmid DNA preparations and reaction mix.
Data are given as means  SD. *P < 0.001
compared with WT.
Analysis of CFTR 50 Region Mutationsc.-674T>C mutation in trans with the F508del mutation. The
c.-674T>C mutation signiﬁcantly reduces luciferase expres-
sion in A549 cells (57.1%, P < 0.001 compared with the WT
construct) and in HepG2 cells (33.2%, P < 0.001).
The c.-869T[8_9] mutation was identiﬁed in a patient
with CF (case 4) in trans with the F508del. The patient
(current age, 41 years) has pancreatic insufﬁciency (PI) and
mild pulmonary expression.
The c.-1308A>G mutation was heterozygous in three
patients with CF (cases 5 to 7) with mild CF and slightly
altered sweat chloride levels. In case 5, it was in cis with the
TG12-T5-470V allele; the patient had the F508del mutation
on the other allele. The patient (current age, 30 years) has
CF with PI, mild pulmonary expression (allergic broncho-
pulmonary aspergillosis and bronchiectasis), nasal poly-
posis, and chronic sinusitis. Case 6 (current age, 32 years)
had the c.-1308A>G mutation and the N1303K mutation on
the other allele. He has mild CF with PI and mild pulmonary
expression with colonization by P. aeruginosa. Case 7 had
c.-1308A>G in trans with G542X; he has PI and mild
pulmonary expression. The c.-1308A>G mutation signiﬁ-
cantly reduces luciferase expression (ie, 33.6%, P < 0.001
compared with the WT construct) in only PanC-1 cells.
The novel c.-1773_-1772delAT mutation was identiﬁed
in two patients with CF (cases 8 and 9). It was in cis with
the 2789 þ 5G>A mutation in case 8 (current age, 20
years), who had the 2789 þ 5G>A/Y849X genotype. This
patient has severe CF with PI and severe pulmonary and
liver expression (ie, cirrhosis with portal hypertension). In
the second case, the c.-1773_-1772delAT was observed in
a patient with CF who has the F508del mutation on the other
allele. The patient (case 9) had PI with mild pulmonary
expression and no liver involvement. The c.-1773_
-1772delAT mutation signiﬁcantly reduced luciferase
expression in PanC-1 cells (55.9%, P < 0.001 compared
with the WT construct) and in HepG2 cells (28.7%, P <
0.001); however, it did not signiﬁcantly modify the
expression in HeLa and A549 cells.The Journal of Molecular Diagnostics - jmd.amjpathol.orgThe novel c.-812T>G mutation was observed in two
unrelated patients with CBAVD (cases 10 and 11) with
normal sweat chloride levels and no other signs or symp-
toms of CF. Both patients had the F508del/U genotype and
we were unable to deﬁne whether the novel variant was in
cis or in trans with the F508del mutation. The novel
c.-812T>G mutation causes increased expression in
HepG2 cells and no changes in the other cell lines. The
c.-2200G>A mutation was identiﬁed in a patient with CF
(case 12; current age, 20 years) with pancreatic sufﬁciency
(PS) and mild pulmonary expression. The patient had the
F508del/TG12-T5-470V genotype, and the c.-2200G>A
variant was in cis with the complex allele. On the same
allele, 1525-1delG was also present. The c.-2200G>A
variant signiﬁcantly increased luciferase expression in HeLa
cells; however, it did not modify gene expression in the
three other types of cells. The novel c.-3632G>T mutation
was observed in two control subjects and in a patient with
CF (case 13) in trans with the F508del. The patient (current
age, 26 years) has CF with PS, mild pulmonary expression
with no colonization, and no liver involvement. The variant
caused higher luciferase expression in PanC-1 cells
(149.7%, P < 0.001 compared with the WT construct) and
a reduction of expression in HepG2 cells (54.1%, P <
0.001) and no effect in the other two types of cells. Finally,
the c.-5914A>G mutation was identiﬁed in a patient with
CBAVD (case 14) with both unidentiﬁed CFTR mutations.
The c.-5914A>G mutation caused a signiﬁcant increase in
gene expression in HeLa cells; however, it did not affect the
other cells.
We then studied the 6000-bp 50 region of CFTR in 20
patients with CF homozygous for the F508del mutation (of
which 10 had severe pulmonary and liver expression and 10
mild pulmonary and no liver expression) to assess whether
promoter mutations would be differently present in such
patients, potentially acting as modiﬁer factors of the CF
phenotype. We recorded only c.-3966T>C and c.-5671C>T
in all the chromosomes. No other mutations were observed.337
Table 5 Features of Patients Bearing Variants Studied in Vitro
Case no. Diagnosis Clinical expression
Sweat chloride
(mEq/L) CFTR genotype FEV 1%
Current age
(years)
1 CBAVD CBAVD alone 38 [N1303K;c.-674T>C]/c.-674T>C 90 32
2 CBAVD CBAVD alone 36 F508del/c.-674T>C 106 28
3 CBAVD CBAVD alone 36 F508del/c.-674T>C 104 30
4 CF PI, mild P, no L 70 F508del/c.-869T[8_9] 78 41
5 CF PI, mild P, nasal polyposis,
chronic sinusitis, no L
76 F508del/[TG12-T5-470V;
c.-1308A>G]
80 30
6 CF PI, mild P, colonization by
P. aeruginosa, no L
68 N1303K/c.-1308A>G 84 32
7 CF PI, mild P, no L 71 G542X/c.-1308A>G 80 17
8 CF PI, severe P, severe L 115 [2789þ5G>A;c.-1773_
-1772delAT]Y849X*
44 20
9 CF PI, mild P, no L 90 F508del/c.-1773_-1772delAT 76 28
10 CBAVD CBAVD alone 40 F508del/c.-812T>G 96 31
11 CBAVD CBAVD alone 23 F508del/c.-812T>G 102 41
12 CF PS, mild P, no L 20 F508del/[1525-1delG;TG12-T5-
470V;c.-2200G>A]y
84 20
13 CF PS, mild P, no L 70 F508del/c.-3632G>T 88 26
14 CBAVD CBAVD alone 22 c.-5914A>G/U 98
*The patient originally had the genotype 2789þ5G>A/unknown; during the present study, we revealed the second mutation (ie, Y849X).
yDuring the study, we revealed the presence of the 1525-1delG mutation in cis with the complex allele TG12-T5-470V and with the c.-2200G>A mutation.
CF, cystic ﬁbrosis; CBVAD, congenital bilateral absence of vasa deferents; FEV 1%, forced expiratory volume in 1 second; L, liver expression; P, pulmonary
expression; PI, pancreatic insufﬁciency; PS, pancreatic sufﬁciency; U, unidentiﬁed mutation.
Giordano et alDiscussion
This is the ﬁrst systematic study of the 6000-bp region at the
50 of CFTR in a large cohort of patients affected by CF and
CFTR-RDs and in control subjects. We found 23 mutations,
of which 9 were novel. To assess their effect on gene
expression, we expressed 17 of these mutations in vitro. We
selected four different cell systems, ie, HeLa (cervix), PanC-1
(pancreas), A549 (pulmonary), and HepG2 (liver) because
three of these cells originate from tissues typically involved
in CF and because the baseline expression of CFTR is
different in these four systems, suggesting that different
regulatory factors (or different amounts of regulatory
factors) of CFTR expression may be present in the four cell
lines. In fact, baseline CFTR expression ranged from noTable 6 Summary of the Features Associated with the Most Importan
Mutation Allele frequency Clinical presentation
c.-674T>C 2.5% in CFTR-RDs CBAVD
c.-869T[8_9] 0.9% in CF CF: PI, mild P, no L
c.-1308A>G 2.6% in CF CF: 5 cases with PI, mild
chronic sinusitis, no L
mild P, colonization by
7 cases with PI, mild P
c.-1773_-1772delAT 1.7% in CF CF: 8 cases with PI, seve
9 cases with PI, mild P
c.-812T>G 1.7% in CFTR-RDs CBAVD
c.-2200G>A 0.9% in CF CF: PS, mild P, no L
c.-3632G>T 0.9% in CF CF: PS, mild P, no L
c.-5914A>G 0.8% in CFTR-RDs CBAVD
CF, cystic ﬁbrosis; CBVAD, congenital bilateral absence of vasa deferents; L, l
pancreatic sufﬁciency.
338expression in HepG2 cells according to previous data19 and
very low expression in HeLa cells20 to intermediate
expression in PanC-1 cells21 and, ﬁnally, high expression in
A549 cells, not in agreement with previous studies.22
Of the 17 mutations tested, 8 signiﬁcantly modiﬁed the
expression of gene reporter, with signiﬁcant differences
among the four cell lines. This suggests that such mutations
impair the interaction of CFTR with regulatory factors that
are produced at different amounts by the different types of
cells. Thus, unlike mutations ofCFTR coding regions (whose
effects involve CFTR activity in all cells), the mutations in
the promoter region may have a different effect on different
tissues, thus inﬂuencing the clinical expression of CF in the
single patient. The correlation of the effect of such mutations
with the clinical expression of patients conﬁrms this viewt Mutations Identiﬁed in the Study
Luciferase expression (cell lines)
Reduction in A549 and HepG2
Reduction in A549 and PanC-1
P, nasal polyposis,
; 6 cases with PI,
P. aeruginosa, no L;
, no L
Reduction in PanC-1
re P, severe L;
, no L
Reduction in PanC-1 and HepG2
Increase in HepG2
Increase in HeLa
Increase in PanC-1, reduction in HepG2
Increase in HeLa
iver expression; P, pulmonary expression; PI, pancreatic insufﬁciency; PS,
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Analysis of CFTR 50 Region Mutations(a summary of these data is available in Table 6). In fact,
the c.-674T>C mutation causes a signiﬁcant reduction in
luciferase expression in A549 and HepG2 cells; it was
identiﬁed in three patients with CBAVD who had a severe
mutation on the other allele; thus, it is conceivable that the
novel mutation has a pathogenic role, acting as a mild
mutation responsible for CBAVD. The c.-869T[8_9] muta-
tion was identiﬁed in a patient with CF in trans with the
F508del. The patient (current age, 41 years) has mild CF,
conﬁrming the pathogenic role of the c.-869T[8_9] mutation,
which causes a strong reduction in luciferase expression in
A549 and PanC-1 cells.
The c.-1308A>G mutation signiﬁcantly reduces lucif-
erase expression in only PanC-1 cells, and it was identiﬁed
in three patients with CF. All show CF with mild pulmonary
expression, and all of them have PI with severe malab-
sorption. In the ﬁrst case, the c.-1308A>G was in cis with
TG12-T5-470V, which usually acts as a mild mutation and
gives rise to CFTR-RDs or to mild CF with PS. We suggest
that the novel c.-1308A>G mutation may act as a negative
modiﬁer factor in this patient, causing impaired CFTR
expression at the pancreatic level, causing PI and altered
sweat chloride levels. Also in the other two cases,
c.-1308A>G identiﬁed in trans with a severe mutation may
act as a disease-causing mutation.
The c.-1773_-1772delAT mutation signiﬁcantly reduces
luciferase expression in PanC-1 and HepG2 cells. It was
found in two patients with CF. The ﬁrst patient had the
severe Y849X mutation23 in trans with the 2789 þ 5G>A
mutation. The c.-1773_-1772delAT mutation was in cis
with the latter and may act as a negative modiﬁer factor,
further reducing the low expression of CFTR due to 2789 þ
5G>A. In fact, 2789 þ 5G>A is a splicing mutation
associated with some residual production of the CFTR
protein.17 It is a mild mutation24; in fact, it was identiﬁed (in
trans with the F508del) in two long aged (65 and 67 years
old) siblings with CF with very mild CF,25 although our
patient showed a severe CF phenotype with PI. Further-
more, the patient had severe liver expression despite the fact
that he was negative for mutations in the A1AT (data not
shown),9 TGF-b, and MDR38 genes and homozygous for
the MBL haplotype with the highest protein activity,8 thus
excluding the possibility that the severe liver phenotype
could depend on mutations in such modiﬁer genes. Simi-
larly, the second patient bearing the c.-1773_-1772delAT
(in trans with the F508del) had a typical CF phenotype
with altered sweat chloride levels and PI.
Three variants caused an increase in luciferase expression
in only one type of cell (ie, the novel c.-812T>G mutation
in HepG2 cells, the novel c.-2200G>A mutation in HeLa
cells, and the c.-5914A>G mutation again in HeLa cells). It
is difﬁcult to deﬁne the role of such variants in the patho-
genesis of the disease. The c.-812T>G mutation, identiﬁed
in two patients with CBAVD, in both cases in trans with
the F508del, could be present in cis with an unidentiﬁed
mutation responsible for the disease. The c.-2200G>AThe Journal of Molecular Diagnostics - jmd.amjpathol.orgmutation was found in a patient with a CFTR-RD with the
F508del/TG12-T5-470V genotype in cis with this latter
complex allele and with the novel 1525-1delG variant.4 This
adult patient showed a CFTR-RD with mild pulmonary
expression (bronchiectasis and colonization by P. aerugi-
nosa). Interestingly, he did not have CBAVD, which is
typically present in CF and in patients with the F508del/
TG12-T5-470V genotype. We suggest that the novel
c.-2200G>A mutation might allow some expression of CFTR
during embryogenesis, counteracting the effect of TG12-
T5-470V and of the 1525-1delG alleles, thus permitting the
development of vasa deferentia. On the other hand, a muta-
tion that enhances CFTR expression and mitigates the effect
of the S549R mutation has been described.26 c.-5914A>G
was identiﬁed in an adult patient with a CFTR-RD with both
undetected mutations who had only bronchiectasis and
a borderline sweat chloride level. Thus, it is difﬁcult to
speculate on its effect. Similarly, it is difﬁcult to establish the
role of c.-3632G>T identiﬁed in a patient with CF with the
F508del on the other allele because c.-3632G>T has
a different effect on PanC-1 cells (enhanced expression) and
on HepG2 cells (reduced expression).
Finally, based on patients with CF with the F508del geno-
type, no differences between the two groups with different
clinical expressionwere evidenced in the 6000-bp region at the
50 of the gene. These data are preliminary because they have
been obtained on a small number of patients (although care-
fully classiﬁed on the basis of the phenotype) all homozygous
for the F508del mutation to reduce the inﬂuence of different
CFTR genotypes on clinical expression.
These data add to existing studies that reported gene
variants in the 50 region that impairs CFTR gene expression,
even if all these studies analyzed only the proximal region of
500 to 1000 bp.13,27 We conclude that the whole portion of
the CFTR promoter of 6000 bp at the 50 of CFTR is strongly
involved in the regulation of gene expression and that
mutations in this region may either reduce or increase gene
expression at different tissue levels, having a role in the
pathogenesis of the disease or in modulation of its phenotype.Acknowledgments
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